Topical bevacizumab is efficacious in the early bleb failure after trabeculectomy.
Żarnowski
Tomas
T
Tulidowicz-Bielak
Maria
M
D000287:Administration, Topical; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D001768:Blister / Q000188:drug therapy*; D003228:Conjunctiva / Q000098:blood supply*; D006801:Humans; D007429:Intraocular Pressure; D057066:Low Tension Glaucoma / Q000188:drug therapy / Q000601:surgery; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D014130:Trabeculectomy; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab